International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel

PURPOSEERBB2 amplification (human epidermal growth factor receptor 2 positivity [HER2(+)]) in metastatic colorectal cancer (mCRC) has important therapeutic implications that necessitate the need for accurate diagnostics. The study purpose was to establish and validate harmonized diagnostic criteria for HER2(+) mCRC among 3 groups (GI-SCREEN-Japan, NCTN-SWOG-USA, and Korea).PATIENTS AND METHODSWe assessed HER2 status by immunohistochemistry (IHC), ERBB2/CEP17 ratio, gene copy number (GCN) by fluorescence in situ hybridization (FISH), and copy number variation (CNV) using two targeted next-generation sequencing (NGS) panels. Tumor samples from 475 and 16 patients with mCRC in exploratory and validation cohorts, respectively, were used for cross-validation of the NGS panels.RESULTSConsensus diagnostic criteria among the 3 groups for HER2(+) mCRC were established as follows: IHC 3+ or IHC 2+ and ERBB2/CEP17 ratio by FISH ? 2.0, tumor content > 10% for surgically resected specimens, and necessary tumor content not defined for biopsy specimens. The median GCN and CNV for HER2(+) patients were 10.9 and 27.7 compared with 2.5 (P < .0001) and 3.5 (P < .0001), respectively, in HER2-negative patients. These findings were validated in a validation cohort (GCN, 16.2 v 2.4 [P = .0002]; CNV, 42.5 v 2.0 [P = .0003]). GCN correlated with CNV in both cohorts (exploratory, r = 0.90; validation, r = 0.97; P < .0001). CNV in cross-validation of the 2 NGS panels also showed a strong correlation (r = 0.98; P < .0001). CNV in patients who fulfilled the consensus criteria was > 4.0 in all, which demonstrates the accuracy of the IHC/FISH criteria and cross-validation of NGS panels.CONCLUSIONWe have established and verified harmonized diagnostic criteria for HER2(+) and demonstrated consistency between IHC/FISH and CNV determined by NGS in mCRC.